Role of ureteric stents in relieving obstruction in patients with obstructive uropathy

The aim of this study is to evaluate the role of ureteric stents in relieving obstruction and improvement of kidney function in patients with obstructive uropathy. This study involved 138 patients with obstructive uropathy with age ranged from 2 months to 73 years. Patients classified into two groups: Group [I]: Includes 57 patients [41.3%], ureteric stents fixed to them; and Group [II]: Includes 81 patients [58.6%] managed by other treatment modalities. All patients underwent clinical assessment, Laboratory and radiologic investigations: At presentation and postoperative. These included: Complete urine analysis, urine culture and sensitivity, serum creatinine, serum urea nitrogen, serum uric acid, serum sodium [Na], serum potassium [K], Fasting blood glucose level and blood picture and plain X-ray [KUB], abdominal ultrasonography [US], diuretic renography and retrograde pyelography. Renal glomerular filtration rate [GFR] was used as an indicator for improvement of renal function after fixation of ureteric stent. In group I: 56 [71.8%] kidneys showed significant recovery compared to 61 kidneys [66.3%]. In group II, there is statistically significant relation between renal perfusion and renal recovery [P < 0.004], statistically significant relation between parenchymal thickness and recovery in both groups [P < 0.0002], statistically significant relation between degree of corticomedullary differentiation and recovery [P < 0.0003] and statistically significant relationship between hemoglobin levels at presentation and the recoverability [P < 0.002]. The predictors of renal recoverability revealed that ureteral stents alone can help in regaining renal function and significant improvement of clinical condition in patients with obstructive uropathy.

Hemosepermia after transrectal ultrasound-guided prostatic biopsy: a prospective study

Trans-rectal ultrasound [TRUS] is a safe, cost-effective, radiation-free imaging modality for evaluation of prostate. But unfortunately, hemospermia is known to be associated with TRUS-guided prostate biopsy. The aim of this study is to measure the incidence and risk factors of hemospermia in patients undergoing TRUS. A prospective observational study involving patients undergoing TRUS for suspected prostate cancer has been conducted at AI-Hussein and Sayed Galal Hospitals. Forty patients were included in the study. Most men [90% = 36 patient] undergoing TRUS-guided prostatic biopsy, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 4 [+/- 1.4] weeks. The number of ejaculations before the complete resolution of hemospermia was 6 [+/- 5.6]. None of the clinical and pathological factors was a significant predictor of the duration of hemospermia. Patients should be adequately counseled before TRUS-guided prostatic biopsy to avoid anxiety and alterations in sexual activity